Acquisitions in Basel-Stadt, Switzerland

Danaher Corporation has acquired Genedata AG, a Basel-based provider of software solutions for biopharmaceutical R&D, and will integrate the company into its Life Sciences segment. The acquisition expands Danaher’s R&D workflow capabilities by adding Genedata’s data-driven informatics and automation tools to accelerate drug discovery and development.

Astorg has signed a binding agreement to acquire CordenPharma, a global contract development and manufacturing organization (CDMO) focused on APIs, excipients and drug products, from International Chemical Investors Group (ICIG). CordenPharma employs over 2,600 people across 11 manufacturing sites and an R&D laboratory in Europe and the US; the founders will reinvest alongside Astorg. The transaction is subject to customary regulatory approvals and terms were not disclosed.

Bain Capital Private Equity and Cinven have entered into definitive agreements to acquire Lonza Specialty Ingredients (LSI), a division of Lonza AG, for a total enterprise value of CHF 4.2 billion. LSI, headquartered in Basel, Switzerland, is a global provider of specialty chemicals for microbial control with ~2,800 employees, and the consortium intends to invest in R&D, bolster production capabilities and use LSI as a platform for buy-and-build consolidation in the sector; the transaction was expected to close in H2 2021.